Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress
The results, including new patient-reported outcome data, were presented at the EADV Congress held October 11-14, 2023, in Berlin.
- The results, including new patient-reported outcome data, were presented at the EADV Congress held October 11-14, 2023, in Berlin.
- New data presented in Berlin demonstrate improvements in both scalp and body itch.
- Importantly, a rapid and significant improvement in scalp itch was observed 24 hours following first application as measured by SI-NRS (P=0.0164).
- Overall, the most common adverse events in the study population (≥2%) included headache (4.6%), diarrhea (3.2%), COVID-19 (2.8%), and nausea (2.1%).